HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART) - a non-inferiority, open-label, phase III randomised trial
Favorite
Share
More Options
8

Open in WPS to view all 8 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
